Market Cap 1.48M
Revenue (ttm) 0.00
Net Income (ttm) 1.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 215,500
Avg Vol 1,691,372
Day's Range N/A - N/A
Shares Out 1.87M
Stochastic %K 72%
Beta 0.32
Analysts Strong Buy
Price Target N/A

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 346 7764
Address:
121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada
buzik
buzik Jan. 14 at 9:36 AM
$PBM WHY MARKET CAP 5 MILION?
0 · Reply
LegendaryDeemo
LegendaryDeemo Jan. 14 at 2:31 AM
Early entries on small-cap rockets aren’t luck — @ReversalFox is a good one to FolloW. Cashed in on plenty of his calls. 💎🔥 Bought in to $APVO $PBM $DVLT $BURU earlier
0 · Reply
Peachtreegal
Peachtreegal Jan. 13 at 11:03 PM
$PBM another one bites the dust
1 · Reply
RuddyRolls
RuddyRolls Jan. 13 at 2:39 PM
$PBM poised for a break out. Value deal of the century! 🚀 🛼 🎢
1 · Reply
JohnTrack
JohnTrack Jan. 13 at 11:03 AM
$PBM Another split? total junk https://www.rapidticker.com/news/pbm-sec-filing-1262ea
1 · Reply
buzik
buzik Jan. 13 at 10:06 AM
0 · Reply
Trader1141
Trader1141 Jan. 13 at 12:11 AM
$PBM so there was a buyback announced? 🤣
0 · Reply
RuddyRolls
RuddyRolls Jan. 12 at 4:11 PM
$PBM GPT summary of my thesis. “PBM is a balance-sheet-backed psychedelic biotech that got trapped in a post-Compass sector unwind, missed the 2025 rebound, attracted an activist invrstor at materially higher prices, and is now undergoing a forced structural reset ahead of Phase 2b data in a friendlier regulatory environment.”
0 · Reply
Jbjb90
Jbjb90 Jan. 12 at 3:16 PM
$PBM https://www.stocktitan.net/news/PBM/psyence-bio-med-approves-2026-financial-strategy-board-authorizes-mkcjn4f0dq8e.html
0 · Reply
Dman_22
Dman_22 Jan. 12 at 2:57 PM
$PBM way over sold at the end of the year! This thing is going to sky rocket once the clinical trial results start to come out and more investment from medical fields start rolling in! I don’t see this staying below $3-5 minimum for very long!😎👌
1 · Reply
Latest News on PBM
Psyence Group Announces Share Consolidation

Apr 17, 2025, 9:39 AM EDT - 9 months ago

Psyence Group Announces Share Consolidation


Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 11 months ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.


buzik
buzik Jan. 14 at 9:36 AM
$PBM WHY MARKET CAP 5 MILION?
0 · Reply
LegendaryDeemo
LegendaryDeemo Jan. 14 at 2:31 AM
Early entries on small-cap rockets aren’t luck — @ReversalFox is a good one to FolloW. Cashed in on plenty of his calls. 💎🔥 Bought in to $APVO $PBM $DVLT $BURU earlier
0 · Reply
Peachtreegal
Peachtreegal Jan. 13 at 11:03 PM
$PBM another one bites the dust
1 · Reply
RuddyRolls
RuddyRolls Jan. 13 at 2:39 PM
$PBM poised for a break out. Value deal of the century! 🚀 🛼 🎢
1 · Reply
JohnTrack
JohnTrack Jan. 13 at 11:03 AM
$PBM Another split? total junk https://www.rapidticker.com/news/pbm-sec-filing-1262ea
1 · Reply
buzik
buzik Jan. 13 at 10:06 AM
0 · Reply
Trader1141
Trader1141 Jan. 13 at 12:11 AM
$PBM so there was a buyback announced? 🤣
0 · Reply
RuddyRolls
RuddyRolls Jan. 12 at 4:11 PM
$PBM GPT summary of my thesis. “PBM is a balance-sheet-backed psychedelic biotech that got trapped in a post-Compass sector unwind, missed the 2025 rebound, attracted an activist invrstor at materially higher prices, and is now undergoing a forced structural reset ahead of Phase 2b data in a friendlier regulatory environment.”
0 · Reply
Jbjb90
Jbjb90 Jan. 12 at 3:16 PM
$PBM https://www.stocktitan.net/news/PBM/psyence-bio-med-approves-2026-financial-strategy-board-authorizes-mkcjn4f0dq8e.html
0 · Reply
Dman_22
Dman_22 Jan. 12 at 2:57 PM
$PBM way over sold at the end of the year! This thing is going to sky rocket once the clinical trial results start to come out and more investment from medical fields start rolling in! I don’t see this staying below $3-5 minimum for very long!😎👌
1 · Reply
RuddyRolls
RuddyRolls Jan. 12 at 2:50 PM
$PBM buy back press release https://finance.yahoo.com/news/psyence-biomed-approves-2026-financial-133000029.html
0 · Reply
AZOZ
AZOZ Jan. 12 at 1:37 PM
$PBM Oversold swing idea 💡
0 · Reply
PaulLaurent
PaulLaurent Jan. 12 at 1:34 PM
🕣 8:30am EST Watchlist udate $EVTV — Government POs headline; already +92% from our first alert with many scalps. Key level: $1.00 break/hold → watch VWAP reclaim and liquidity. $OSRH — Binding term sheet at affiliate Vaximm; event-driven tape. Look for volume build and prior HOD reclaims. $BDSX — Prelim Q4/FY25 update; watch for revenue cadence and margin color. Trade clean pivot reclaims. $PBM — 2026 strategy + board-approved buyback; monitor size/timing and borrow. Thin tape can rip. $ICCM — CEO letter highlights record Q4/FY25 ProSense momentum; scalp-first with tight risk on fades. Tone: Catalyst carry into the open—favor VWAP/pivot reclaims, trim into strength, and keep stops tight if volume thins.
2 · Reply
JimBull
JimBull Jan. 12 at 1:33 PM
$PBM no debt $12M cash and now Buyback!
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 12 at 1:31 PM
$PBM PBM I don't see numbers on the buyback. Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
0 · Reply
buzik
buzik Jan. 12 at 10:24 AM
1 · Reply
RuddyRolls
RuddyRolls Jan. 12 at 1:51 AM
$PBM gets a plug in UC Berkley's The Microdose enews/ substack this week. Lifting their PR game! "Toronto-based biomed company Psyence announced on Monday that it is now producing “high-purity ibogaine hydrochloride (ibogaine HCl) derived from a naturally extracted, ethically sourced supply in Africa,” compliant with good manufacturing practices." https://themicrodose.substack.com/p/compass-pathways-partnering-with
1 · Reply
RuddyRolls
RuddyRolls Jan. 12 at 1:39 AM
$PBM https://www.tipranks.com/news/the-fly/psyence-biomedical-announces-psilocybin-longevity-research-program-thefly "Psyence BioMed is developing an accelerated preclinical protocol designed to evaluate whether psilocybin influences biological mechanisms tied to aging. The study will examine biomarkers related to cellular stress, inflammation, mitochondrial function, and behavioural indicators associated with healthspan and lifespan. The Company has commenced the project, with full acceleration anticipated early in the new year following ethics approval. The research will be conducted under the leadership of Dr. Tanya Calvey, PhD, an internationally recognized neuroscientist specializing in translational neuropsychopharmacology. Dr. Calvey’s work bridges human neuroimaging, molecular biology, and neurohistology to explore how psychoactive compounds influence long-term brain health and cellular resilience."
0 · Reply
RuddyRolls
RuddyRolls Jan. 12 at 1:37 AM
$PBM "Psyence Biomedical (Psyence BioMed) has dosed multiple participants in its ongoing Phase IIb clinical study assessing nature-derived psilocybin alongside psychotherapy as a potential therapy for adjustment disorder in palliative care." https://www.clinicaltrialsarena.com/news/psyence-biomed-doses-multiple-patients-study/
0 · Reply
Fede_Tech
Fede_Tech Jan. 11 at 10:34 PM
$PBM Remember to vote against on the 3rd point called Share Consolidation (reverse split). You have time until January 20th.
1 · Reply
MichaelBestwick
MichaelBestwick Jan. 11 at 6:59 PM
$PBM VOTE NO on reverse split Up to 250-1
0 · Reply
SmilerJon
SmilerJon Jan. 10 at 5:21 PM
$PBM I wonder how many people this applies to
0 · Reply